NEW YORK, Jan 26 - A trial to determine whether a patent Amersham Pharmacia Biotech holds for DNA chemistries is valid and enforceable has been delayed from January 29 until March, AP Biotech said Friday.

The judge in the jury trial, which stems from a lawsuit AP Biotech brought against Applied Biosystems and its sister company Celera, will use the extra time to decide whether the patent issue also includes Applied Biosystems’ soon-to-be-released Version 3 of  its “Big Dye” products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.